Effect of intravitreal injection of Conbercept in the treatment of diabetes macular edema and its influence on serum VEGF and SDF-1 levels
Objective:To investigate the effect of intravitreal injection of Conbercept(trade name:"Langmu")on diabetes macular edema(DME)and its effect on the levels of serum vascular endothelial growth factor(VEGF)and human stromal cell derived factor 1(SDF-1).Method:103 DME patients in our department from May 2020 to February 2022 were selected and randomly divided into laser group and Langmu group.51 patients in the laser group were received fundus laser photocoagulation treatment,while 52 patients in the Langmu group were received laser photocoagulation combined with Langmu treatment.The visual acuity,macular thickness,vascular growth factor,and adverse reactions of the two groups were compared.Result:After 1,2,and 3 months of treatment,the best corrected visual acuity(BCVA)in the Langmu group was higher than that in the laser group(P<0.05).After 3 months of treatment,the Central Macular Thickness(CMT)and Subfoveal Choroidal Thickness(SFCT)of the Langmu group were lower than those of the laser group(P<0.05);The serum levels of VEGF and SDF-1 in the Langmu group were lower than those in the laser group(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups.Conclusion:Intravitreous injection of Langmu as an adjuvant therapy for DME can effectively inhibit vascular growth in the vitreous body,reduce macular edema,and improve patients'vision with high safety.
NETL
NSTL
万方数据
